Can Fite Biopharma Ltd (CANF)
$2.32
Performance
- $2.21$2.40$2.32
4.62%
Downside
Day's Volatility :7.8%
Upside
3.33%
- $1.81$4.69$2.32
21.98%
Downside
52 Weeks Volatility :61.41%
Upside
50.53%
Returns
| Period | Can Fite Biopharma Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -6.07% | 0.0% |
6 Months | 7.41% | 0.0% |
1 Year | -17.14% | 0.0% |
3 Years | -87.18% | -22.3% |
Highlights
Market Capitalization | 13.4M |
Book Value | $0.01 |
Earnings Per Share (EPS) | -2.6 |
PEG Ratio | 0.0 |
Wall Street Target Price | 13.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -1183.23% |
Return On Assets TTM | -53.15% |
Return On Equity TTM | -142.49% |
Revenue TTM | 743.0K |
Revenue Per Share TTM | 0.3 |
Quarterly Revenue Growth YOY | -21.3% |
Gross Profit TTM | 810.0K |
EBITDA | -8.2M |
Diluted Eps TTM | -2.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.39 |
EPS Estimate Next Year | -0.73 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 474.57%
Technicals Summary
Sell
Neutral
Buy
Can Fite Biopharma Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Can Fite Biopharma Ltd | -3.33% | 7.41% | -17.14% | -87.18% | -90.29% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Can Fite Biopharma Ltd | NA | NA | 0.0 | -1.39 | -1.42 | -0.53 | NA | 0.01 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Can Fite Biopharma Ltd | NA | $13.4M | -90.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Can Fite Biopharma Ltd
Decreasing Revenue
Revenue is down for the last 8 quarters, 205.0K → 155.0K (in $), with an average decrease of 3.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -1.76M → -1.65M (in $), with an average increase of 6.7% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 54.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 156.4%
Company Information
can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.
Organization | Can Fite Biopharma Ltd |
Employees | 8 |
CEO | Dr. Pnina Fishman Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.32
-0.34%
Keyarch Acquisition Corp
$2.32
-0.34%
Connexa Sports Technologies Inc
$2.32
-0.34%
Us Value Etf
$2.32
-0.34%
First Wave Biopharma Inc
$2.32
-0.34%
Global X Msci Next Emerging
$2.32
-0.34%
Fat Projects Acquisition Corp
$2.32
-0.34%
Capital Link Global Fintech
$2.32
-0.34%
Applied Uv Inc
$2.32
-0.34%